Premium
Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait
Author(s) -
Kanyike Fb,
Abdul-Salam Sa,
B Prakash,
A Sharhan,
N Wahib,
Youssef Ah
Publication year - 1999
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1046/j.1365-2516.1999.00314.x
Subject(s) - medicine , haemophilia , recombinant factor viia , haemophilia a , coagulation , surgery , factor viia , complication , recombinant dna , tissue factor , biochemistry , chemistry , gene
Development of inhibitors is a known complication in some haemophiliacs receiving coagulation factor replacement therapy. We report on the successful management of a young boy with haemophilia A with inhibitor using recombinant factor VIIa. We had failed to control bleeding in this patient following his circumcision, despite infusion with high doses of factor VIII concentrate for 2 weeks. Recombinant factor VIIa is a useful ‘factor VIII bypassing agent’ for the control of bleeding in patients with haemophilia A and B who develop inhibitors. We suggest that severely affected haemophiliacs should be absolved of ritual circumcision as a protective measure against what might become a life‐threatening haemorrhage – especially in those with inhibitors.